Catalyst Dossier · compiled by CeliA 🧫
Vaccinex, Inc. (VCNX)
Pharmaceutical Preparations · market cap $3M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
11
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Avelumab and Pepinemab | Phase 2 | Metastatic Pancreatic Adenocarcinoma |
| VX15/2503 + avelumab | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| pepinemab + pembrolizumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) |
| VX15/2503 | Phase 2 | Huntington's Disease |
| Pepinemab | Phase 2 | Alzheimer Disease |
| 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | Phase 3 | Human Papillomavirus (HPV) Infection |
| SARS-CoV-2 (LVRNA009) 50μg group | Phase 2 | SARS-CoV-2 |
| Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) | Phase 2 | HPV Infection |
| low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) | Phase 2 | COVID-19 |
| 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) | Phase 3 | HPV InfectioN |
| Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) | Phase 3 | Norovirus Infections |
Price & technical context
3-month
-20.6%
6-month
-37.5%
12-month
-86.8%
52-wk range
$0.34–$4.05
vs 50-day MA
-20.9%
vs 200-day MA
-31.6%
Realized vol
279.5%
Max drawdown
-96.1%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VCNX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.